Recently, the expert group of the National Health Commission authoritatively promulgated the Chinese Guidelines for the Treatment of Chronic Pain Disorders with Non-opioid Analgesics; Biqi Capsule, a product of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited for treatment of rheumatism and bone pain was listed in the Guidelines and rated as high quality evidenced (A) and strongly recommended (1) drug. The Guidelines was first published in 39th issue of the Chinese Medical Journal (a dual-core journal) in 2023.

In recent years, the company has made great progress in the basic research and traditional medicine research of proprietary Chinese medicine in inhibiting inflammatory factors and maintaining the balance of bone metabolism. Biqi Capsule (1A) has a clear anti-inflammatory mechanism, and is mostly used in treating clinical pain diseases such as rheumatic/rheumatoid arthritis and osteoarthritis.

The Guidelines was formulated by the expert group of the pain diagnosis and treatment special ability training project of the Capacity Building and Continuing Education Center of the National Health Commission after strict argumentation, which was written by 14 national authoritative experts jointly, aiming at providing reasonable and standardized guidance on the diagnosis and treatment and medication for pain departments, neurology, surgery, orthopedics, rheumatology and immunology departments, rehabilitation departments, Chinese medicine doctors and clinical pharmacists in different levels of hospitals.

Chronic pain refers to pain that lasts or recurs for more than 3 months, suffered by more than 20% of the global population, and about 2/3 of patients with chronic pain are accompanied by cognitive and emotional disorders. Recently, the International Classification of Diseases (ICD-11) classified chronic pain for the first time, and identified chronic secondary musculoskeletal pain as chronic secondary pain syndrome caused by injury and other diseases, and its pathogenesis was mainly the nociceptive pain.

In the treatment with non-opioid drugs, non-steroidal anti-inflammatory and analgesic drugs are often used to treat this kind of pain. With the increasing evidence-based medicine evidence of proprietary Chinese medicine, and with the characteristics of good efficacy and less adverse reactions, there are more drugs available in clinical treatment.

In the guidelines, the Biqi Capsule produced by Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is made of ten ingredients: nux vomica, codonopsis pilosula, salvia miltiorrhiza, Atractylodes macrocephala, Poria, Notoginseng Radix, Glycyrrhiza uralensis, Ligusticum Chuanxiong, Lumbricus and Achyranthes bidentata.

Biqi Capsule adopts the concept of "health manager for patients with rheumatic bone pain", integrating the essence of traditional medicine while making innovation, boosting the vigorous development of health China and modernization of traditional Chinese medicine.